Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) [Seeking Alpha]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Seeking Alpha
GLP-1s account for roughly 25% of HIMS revenue; losing this segment threatens growth and has triggered a 60% stock drawdown. Despite management's $6.5B 2030 target, legal uncertainty and regulatory scrutiny justify HIMS trading at a discount near 2x forward revenue. Future growth opportunities exist in diagnostics, labs, and international expansion, but execution and regulatory clarity are now paramount. This idea was discussed in more depth with members of my private investing community, The Pragmatic Investor. Learn More » artisteer/iStock via Getty Images Thesis Summary Hims & Hers Health, Inc. ( HIMS ) has built one of the most successful consumer health platforms in the U.S. But HIMS really began to take off when it started offering compounded GLP-1s. Though More on my IG service Macro moves markets, and this is what I do at The Pragmatic Investor Join today and enjoy: - Weekly Macro Newsletter - Access to our Portfolio - Deep dive reports on stocks.
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (NYSE:HIMS) was given a new $31.00 price target on by analysts at Deutsche Bank Aktiengesellschaft. They now have a "hold" rating on the stock.MarketBeat
- Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
- Hims & Hers Health: Don't Fall For The Hysteria [Seeking Alpha]Seeking Alpha
- HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 2/4/26 - Form 4
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- HIMS's page on the SEC website